FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression

To our knowledge, these are the first data to compare FGFR-directed therapy with chemotherapy in patients with <i>FGFR</i>-altered UC, showing comparable efficacy and manageable safety. Exploratory testing suggested <i>FGFR3</i> DNA alterations in association with <i>FGFR1</i>/<i>3</i> mRNA overexpression may be better predictors of rogaratinib response.